Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer

Next Previous
X
Search
Trial Profile

Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oregovomab (Primary) ; Antiemetics; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors OncoQuest

    • Most Recent Events

    • 14 Oct 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Apr 2024.
    • 20 Oct 2022 Planned primary completion date changed from 31 Dec 2021 to 30 Apr 2023.
    • 01 Sep 2021 According to an OncoQuest media release, first patient has been enrolled in the trial. This study is supported by Korean Government's K-Master program (KM-21) under the guidance of Prof. Kim YH at the Korea University Anam Hospital and Professor Park KH at Korea University College of Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top